Alimera Sciences Nears Profitability as Growth Accelerates Post-Acquisition Alimera Sciences, now part of ANI Pharmaceuticals, is projected by analysts to reach profitability in 2025, following a reduction in losses and ambitious growth targets. The company faces a high debt-to-equity ratio, but recent performance improvements and new ownership could help it achieve breakeven within the next year.34